February 2026 Research Update

How well current complement blockers are covering symptoms

Across this month, the studies painted a consistent picture: complement inhibitors can improve signs of hemolysis and reduce transfusion needs compared with placebo, but many people still have anemia and fatigue even when on long-term C5 inhibitors. Real-world surveys described ongoing day-to-day burden despite treatment, including low hemoglobin, tiredness, and healthcare use. At the same time, evidence reviews continued to support that multiple complement inhibitors can help key blood outcomes in people new to these drugs, while head-to-head differences between drugs remain uncertain in the current trial network. [1] [2] [3]

In routine care surveys of people taking eculizumab or ravulizumab, many remained anemic and reported fatigue and reduced quality of life, and some still needed transfusions or had hospitalizations. One multi-country dataset reported that most patients had hemoglobin below 12 g/dL at the time of survey and many had received at least one transfusion in the prior year. A Japan-focused survey similarly found that patient-reported tiredness and shortness of breath were common, even though the share of patients with high LDH (a marker of ongoing red cell breakdown) was much lower at the survey than at diagnosis. [1] [2]

A systematic review that connected several randomized trials through indirect comparisons reported that ravulizumab, eculizumab, crovalimab, and pegcetacoplan each improved outcomes like transfusion avoidance and hemoglobin stabilization versus placebo in complement inhibitor-naive adults. Because the comparisons between active drugs were mostly indirect and based on a sparse evidence network, the results were presented as early, hypothesis-generating signals rather than definitive rankings. This helps explain why trial results can look encouraging while real-world surveys still show that symptoms and anemia may not fully resolve for everyone. [3] [1]

What this means for patients and caregivers

This month adds clarity that symptom burden is still common for many people on C5 inhibitors, even when lab markers of hemolysis look better, so day-to-day impact remains an important part of the PNH story. The evidence about placebo-controlled benefit of complement inhibitors in people starting treatment is supported by randomized trials, but the question of which drug is best for which person is still not fully answered by the current mix of studies. These findings mainly add understanding about where current therapies help and where gaps remain, rather than changing anything immediately. [1] [2] [3]

Early signals about newer complement pathway approaches

This month included early, smaller-scale evidence suggesting that some newer complement pathway strategies may help address persistent hemolysis or anemia in certain situations, but the data are not broad enough to predict what most people will experience. A small case series described improved hemoglobin and less transfusion need after switching from pegcetacoplan to iptacopan, without reported breakthrough or extravascular hemolysis after the switch. Separately, a modeling study focused on danicopan (an add-on treatment that targets a different part of complement) mapped how drug exposure relates to inhibition of the alternative complement pathway, supporting the dosing approach used in studies. [4] [5]

In three adults switched from pegcetacoplan to iptacopan, the report described higher hemoglobin and a drop in transfusion requirements after the change, and it did not describe new episodes of breakthrough or extravascular hemolysis during follow-up. Because this was only three people, it is best viewed as a clinical signal that switching within complement-targeting options may work well for some individuals, rather than proof of typical outcomes. [4]

The danicopan analysis did not test symptom improvement directly, but it measured how danicopan levels in the body relate to suppression of alternative pathway activity, a lab readout of its biological effect. The simulations suggested that the studied dosing schedules could keep pathway activity strongly suppressed across different meal conditions, and the analysis did not find a clinically meaningful relationship between higher exposure and safety signals in the available data. For patients, this type of work is mainly about confirming that the drug behaves predictably in the body, which is a necessary step alongside clinical outcome studies. [5]

What this means for patients and caregivers

These reports are mainly early research and small clinical observations, so they are more about building the evidence base than providing clear expectations for most patients right now. The iptacopan switch case series suggests that some people who are not doing well enough on one complement approach may do better on another, but it is still uncertain how often that happens and who is most likely to benefit. The danicopan modeling helps explain the drug's biological effect and supports how it has been studied, but it does not replace clinical trial results that measure outcomes people feel, like fatigue or function. [4] [5]

What individual cases highlighted this month

This month’s case-based papers mainly reinforced two real-world points: PNH can present with classic symptoms like dark urine from active hemolysis, and PNH sometimes overlaps with bone marrow failure conditions like aplastic anemia. The cases also emphasized that confirming the diagnosis and understanding the disease subtype can shape how treatment is approached, especially when more than one blood problem is present. Because these are individual cases and small case series, they illustrate possibilities rather than showing what is most common. [6] [7] [8]

One single-patient report described a person with recurrent dark urine and severe intravascular hemolysis who improved after starting eculizumab, including resolution of hemoglobin in the urine and stabilization of hemoglobin over a few months. The report also described how sensitive blood testing can show the size of the PNH clone (the group of affected blood cells), which helps confirm the diagnosis. This kind of case helps patients recognize that PNH symptoms can be dramatic at first and may improve with complement blockade, but it does not predict the range of responses across the broader community. [6]

Another case report focused on the overlap of aplastic anemia and PNH and highlighted that sorting out both conditions can be challenging, with discussion of a possible immune-related link between marrow damage and expansion of the PNH clone. A separate three-case article emphasized classifying PNH carefully and considering both complement inhibition and treatment of underlying marrow failure when present, but it did not provide new comparative outcome results. Together, these papers underscore that not all PNH looks the same, especially when bone marrow failure is part of the picture. [7] [8]

What this means for patients and caregivers

These case-based publications may matter most for understanding the range of PNH presentations and why some people need evaluation for overlapping bone marrow problems. They do not provide the kind of evidence that can estimate typical benefits or risks, because they describe single patients or a few cases. Still, they help clarify that PNH can involve both hemolysis-related symptoms and bone marrow failure features, and that this overlap can influence how doctors frame the problem and track response over time. [6] [7] [8]